Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Tafasitamab (TAFA) combined with lenalidomide (LEN) showed a median overall survival (OS) of 45.7 months in second-line treatment and 15.5 months in third-line treatment, significantly outperforming other therapies like Bendamustine-Rituximab (median OS 11.49 months, euro23 958 (BR)) with 11.49 months in second-line and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) with 12.0 months in third-line settings. TAFA + LEN also had significantly better OS compared to POLA + BR (95% CI (HR) 0.41; p = 0.026) and BR (HR 0.39; p = 0.014).
• Progression-free survival (pooled data: HR 0.39 (95% CI 0.29, 0.53 (PFS)) was improved in the tafasitamab group, with a 1-year PFS of 0.47 (95% CI, 0.37 to 0.57), higher than CAR T-cell therapy (0.40; 95% CI, 0.35 to 0.46) in autologous stem-cell transplant (ASCT)-ineligible patients. TAFA + LEN also showed a significantly better PFS compared to BR (HR 0.39; p < 0.001).
• TAFA + LEN demonstrated a longer duration of response (DOR) compared to POLA + BR (HR 0.34; p = 0.045) and BR (HR 0.35; p < 0.001), along with an improved complete response rate (CRR) over BR (Odds Ratio 2.43; p = 0.004).
• The reviewed studies did not explicitly mention safety outcomes or adverse effects related to tafasitamab-cxix or other drugs, so there is no safety information available.
• Evidence highlights a distinction in effectiveness outcomes between ASCT-eligible and ASCT-ineligible groups. The 1-year progression-free survival (PFS) for tafasitamab in the ASCT-ineligible group was 0.47 (95% CI, 0.37 to 0.57), outperforming other therapies, including CAR T-cell therapy (PFS: 0.40, 95% CI, 0.35 to 0.46). No significant difference in PFS was observed between CAR T-cell therapy and chemotherapy followed by ASCT in the ASCT-eligible group.